Here are 1-2 analogies to describe Regenxbio (RGNX):

• The Novartis of gene therapy, specializing in genetic and eye conditions.
• A gene therapy pioneer, much like how Genentech revolutionized medicine with recombinant DNA in its early days.

• NAV Technology Platform: A proprietary gene therapy platform utilizing adeno-associated virus (AAV) vectors to deliver genetic material for therapeutic purposes.
• RGX-314: An investigational gene therapy in late-stage clinical development for treating wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases.
• Investigational Gene Therapies for Rare Diseases: A pipeline of clinical and pre-clinical stage gene therapy candidates targeting severe rare genetic disorders such as Hunter syndrome (RGX-121) and Hurler syndrome (RGX-111).
• Licensing Gene Therapy Technology: Provides access to its proprietary NAV Technology Platform to pharmaceutical partners for the development and commercialization of gene therapies, exemplified by Zolgensma for spinal muscular atrophy.

Major Customers of Regenxbio (RGNX)

Regenxbio (RGNX) is a biotechnology company focused on gene therapy. Its business model primarily involves developing gene therapy product candidates and licensing its proprietary NAV Technology Platform to other pharmaceutical companies, as well as partnering for the development and commercialization of its product candidates. Therefore, Regenxbio sells primarily to other companies.

Its major customers and partners include:

• Roche Holding AG (through its subsidiary Genentech): RHHBY (OTC symbol for Roche)

  Genentech uses Regenxbio's NAV Technology Platform for VABYSMO (faricimab), a treatment for eye diseases like wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Regenxbio receives royalties on VABYSMO sales.

• AbbVie Inc.: ABBV

  AbbVie is a key partner for RGX-314 (now ABBV-RGX-314), a gene therapy product candidate for wet AMD and diabetic retinopathy. AbbVie is responsible for the global development and commercialization of this program, with Regenxbio eligible for milestone payments and royalties.

• AGC Biologics
• Catalent, Inc. (CTLT)
• WuXi AppTec Co., Ltd. (WXXWY)

Curran M. Simpson, President and Chief Executive Officer

Curran M. Simpson was appointed President and Chief Executive Officer and a member of the Board of Directors in July 2024. He previously served as the company's Chief Operating Officer, leading functions such as Research & Clinical Development, Corporate Strategy, Manufacturing & Quality, Regulatory, and Commercial Operations. Mr. Simpson joined REGENXBIO in 2015, initially serving as Chief Technology and Operations Officer. Prior to joining REGENXBIO, he was the Regional Supply Chain Head for North America and Interim Chief Operating Officer at GlaxoSmithKline (GSK). He also served as interim CEO of Human Genome Sciences (HGS), where he oversaw its integration into GSK, and held roles as Senior Vice President of Operations and Vice President of Manufacturing Operations at HGS.

Mitchell Chan, Executive Vice President and Chief Financial Officer

Mitchell Chan was appointed Executive Vice President and Chief Financial Officer of REGENXBIO in September 2024. He brings nearly two decades of financial leadership experience in the life sciences industry. Most recently, Mr. Chan served as an Operating Partner at Catalio Capital Management, LP, a venture capital firm, where he acted as CFO for several portfolio companies and advised on investments. From 2018 to 2021, he was the Chief Financial Officer of Viela Bio, Inc., a clinical-stage biotechnology company, where he oversaw a successful initial public offering and its acquisition by Horizon Therapeutics plc for $3.1 billion. Earlier in his career, Mr. Chan held leadership roles in finance and investor relations at AstraZeneca and within the Roche Group, including at Genentech and F. Hoffmann-La Roche AG.

Steve Pakola, M.D., Chief Medical Officer

Dr. Steve Pakola is the Chief Medical Officer for REGENXBIO. Before joining REGENXBIO, Dr. Pakola served as Chief Medical Officer at Aerpio Pharmaceuticals. He has over 20 years of biopharmaceutical experience, including key leadership roles in preclinical and clinical development, regulatory affairs, and medical affairs, with therapeutic area expertise in retinal disorders.

Olivier Danos, Ph.D., Chief Scientific Officer

Dr. Olivier Danos is the Chief Scientific Officer for REGENXBIO. Prior to REGENXBIO, he was Senior Vice President, Cell and Gene Therapy at Biogen Inc., where he led efforts in gene transfer and genome engineering technologies. Dr. Danos also co-founded Lysogene, a gene therapy company.

Patrick J. Christmas II, J.D., Chief Legal Officer

Patrick J. Christmas II is the Chief Legal Officer at REGENXBIO. He has more than 15 years of leadership and public market experience in the life sciences industry, having managed legal, compliance, government affairs, and business development functions at various biotech and pharmaceutical companies.

The clear emerging threat to Regenxbio (RGNX) is the development of competing gene therapies for retinal diseases that utilize a less invasive administration route. Regenxbio's lead product candidate, ABBV-RGX-314, requires a subretinal surgical procedure for delivery. Companies like 4D Molecular Therapeutics, with their product candidate 4D-150, are developing AAV-based gene therapies for wet age-related macular degeneration (wet AMD) designed for intravitreal injection, which is a routine office procedure. If 4D-150 or similar intravitreally-delivered gene therapies demonstrate comparable efficacy and safety profiles to ABBV-RGX-314, their significantly less invasive delivery method could offer a substantial competitive advantage, potentially disrupting the market for RGNX's subretinally-administered therapy.

Regenxbio (RGNX) develops gene therapies for various diseases. The addressable markets for their main product candidates are as follows:

• RGX-121 (Hunter Syndrome/Mucopolysaccharidosis Type II - MPS II): The total addressable market for RGX-121 is estimated to reach global sales of $460 million by 2030. Hunter syndrome is an ultra-rare genetic disorder affecting approximately 1 in 100,000 to 170,000 births.
• RGX-111 (Mucopolysaccharidosis Type I - MPS I): The revenue for RGX-111 is expected to reach an annual total of $10 million globally by 2039.
• RGX-202 (Duchenne Muscular Dystrophy - DMD): This product candidate is projected to reach an annual revenue of $163 million by 2039 in the U.S. A commercial launch is anticipated in 2027, when the majority of the prevalent market is expected to be available.
• ABBV-RGX-314 (wet Age-related Macular Degeneration - wet AMD, Diabetic Retinopathy - DR): Diabetic retinopathy affects nearly 10 million people in the United States alone. ABBV-RGX-314 has the potential to help millions of people globally who are living with wet AMD and DR.

Regenxbio (RGNX) is poised for future revenue growth over the next 2-3 years, driven primarily by advancements and potential commercialization of its gene therapy pipeline, strategic partnerships, and existing royalty streams.

1. Launch of RGX-121 for Hunter Syndrome (MPS II): RGX-121 is on track for potential FDA approval in early 2026, with a Prescription Drug User Fee Act (PDUFA) date set for February 8, 2026. If approved, this one-time gene therapy for Mucopolysaccharidosis II is expected to generate a meaningful new revenue stream for the company.

2. Commercialization of RGX-202 for Duchenne Muscular Dystrophy (DMD): Regenxbio completed enrollment for its pivotal trial of RGX-202, with topline data anticipated in early Q2 2026. A Biologics License Application (BLA) submission is planned for mid-2026, and the company has already initiated commercial manufacturing to support an expected approval and launch in 2027. RGX-202 is positioned as a potential best-in-class gene therapy for DMD.

3. Advancement of ABBV-RGX-314 for Retinal Diseases (Wet AMD and Diabetic Retinopathy): Through its partnership with AbbVie, the ABBV-RGX-314 program has completed pivotal trial enrollments for wet age-related macular degeneration (AMD), with topline data expected in Q4 2026. This collaboration features a 50/50 profit share, and AbbVie will lead the commercial efforts, enhancing market reach and potential for significant market capture due to its one-time administration.

4. Strategic Partnerships and Milestone Payments: Regenxbio benefits from strategic collaborations, notably with Nippon Shinyaku for RGX-121 and RGX-111, and with AbbVie for ABBV-RGX-314. These partnerships provide non-dilutive funding through upfront payments and potential milestone achievements (e.g., $110 million upfront payment from Nippon Shinyaku in Q1 2025), which are expected to continue contributing to revenue as pipeline assets advance.

5. Ongoing Royalty Revenue from Zolgensma: Regenxbio continues to receive royalty revenues from Novartis's Zolgensma, a gene therapy that utilizes Regenxbio's proprietary NAV Technology Platform. This existing passive income stream provides a foundational component of the company's overall revenue.

Share Issuance

• In March 2024, REGENXBIO priced an underwritten public offering of approximately 4.57 million shares of common stock at $23.00 per share and 1.52 million pre-funded warrants at $22.9999 per warrant, with expected gross proceeds of approximately $140.0 million.
• In January 2021, REGENXBIO closed an underwritten public offering of 4,260,000 shares of common stock at $47.00 per share, including the full exercise of the underwriters' option to purchase an additional 639,000 shares, resulting in total gross proceeds of approximately $230.3 million.

Inbound Investments

• In May 2025, REGENXBIO entered into a non-dilutive, limited recourse royalty bond agreement of up to $250 million with Healthcare Royalty (HCRx), receiving $150 million at closing. An additional $50 million is expected by April 2027 upon achievement of ZOLGENSMA sales milestones, and another $50 million upon mutual agreement.
• In March 2025 (announced January 2025), REGENXBIO established a strategic partnership with Nippon Shinyaku for RGX-121 and RGX-111, receiving an upfront payment of $110 million and being eligible for up to an additional $700 million in development, regulatory, and sales milestones.
• In November 2021, REGENXBIO closed a collaboration and license agreement with AbbVie for RGX-314, which included an upfront payment of $370 million to REGENXBIO and potential for up to $1.38 billion in additional development, regulatory, and commercial milestones.
• In December 2020, REGENXBIO sold a portion of its royalty rights from Novartis Gene Therapies' Zolgensma to entities managed by Healthcare Royalty Management, LLC for a gross purchase price of $200 million.

Capital Expenditures

• REGENXBIO is investing in manufacturing capabilities with the aim of aligning costs with biologics, enhancing the benefit-to-risk ratio of its products.
• In Q3 2025, REGENXBIO planned to initiate commercial supply manufacturing for RGX-202 to support an expected launch in 2027. Commercial manufacturing batches for RGX-202 have been produced, and process qualification is nearing completion.